The overexpression of microRNA-155 (miR-155), a short, single strand of ribonucleic acid encoded by the miR-155 host gene, promotes the growth of blood vessels in tumors, tumor inflammation, and metastasis. As a therapeutic target, miR-155 could potentially provide a new avenue of treatment when targeted with drugs to suppress its activity.
MiR-155, which plays an important role in various physiologic and pathologic processes, is considered an indicator of poor prognosis for breast cancer patients when it is overexpressed. Controlling miR-155 expression could inhibit malignant growth.
“Our study shows that miR-155 is a driver of new blood vessel growth in tumors,” said study lead author Jin Q. Cheng, MD, PhD, senior member of the Cancer Biology and Evolution Program at Moffitt Cancer Center in Tampa, Florida. “It also plays a critical role in metastasis, especially in triple-negative breast cancer. This makes miR-155 both a prognostic marker and a potential therapeutic drug target.”
According to the researchers, several studies show that miR-155 is frequently increased in various human malignancies, including breast, lung, pancreatic, and colon cancers. It also regulates a number of cell processes, including growth, survival, migration, and invasion. Their study demonstrates that miR-155 promotes new blood vessel growth in breast cancer by targeting the natural tumor suppressor VHL, part of an important cancer pathway for a cascade of events.
“Further studies could provide insight into the role of miR-155 in inflammation that leads to tumor progression,” noted the researchers, who found elevated miR-155 in triple-negative breast cancer, a form of breast cancer that does not express the genes for estrogen, progesterone, and human epidermal growth factor receptors. This study was published in Oncogene (2013; doi:10.1038/onc.2012.636).
“Our findings are important for a number of reasons,” Cheng said. “We have shown that miR-155 targets and downregulates the tumor suppressor VHL and that miR-155 contributes to tumor growth and spread. This makes miR-155 a critical therapeutic target in breast cancer.”